FDA: ‘No Convincing Evidence’ Hormones In Cosmetics Pose Health Risk
This article was originally published in The Rose Sheet
Executive Summary
FDA says it continues to monitor the issue of estrogens and progesterone in cosmetic products; however, in a recently published study an agency scientist notes that to date, FDA has found “no convincing evidence” that cosmetics containing the substances pose health risks. Products surveyed largely were found to be labeled properly, belying concerns that consumers may be exposing themselves unwittingly.
You may also be interested in...
Heavy Metals, Estrogenics Among Research Priorities For FDA's Cosmetics Office
FDA’s Office of Cosmetics and Colors continues with surveys to detect the presence of controversial ingredients in cosmetics, including asbestos in talc-containing products. Office’s Deputy Director Patricia Hansen provides an overview at the Personal Care Products Council’s recent scientific summit.
ICCS President Hill On Growing Regulatory Confidence In Alternative Testing Methodologies
In the year since its establishment, the International Collaboration on Cosmetics Safety has worked to engage with regulators as they build frameworks for assessing cosmetic safety without animal tests. ICCS president and CEO Erin Hill discusses current challenges and what lies ahead.
Hawaii Contemplates Measures To Increase Access To Sunscreens Following Sunscreen Bans
Hawaii looks to “ease the burden” of finding reef-safe sunscreens by distributing it to sunseekers at beaches. The proposed legislation comes roughly three years after the Aloha State began prohibiting sale of oxybenzone- or octinoxate-containing sunscreen products due to concerns about potential harm to coral.